Quinapril Tablets USP
CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.
Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.
Subpotent Drug
Cause type: Wrong potency / content
Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.
Quinapril Tablets USP, 5 mg, Rx only, 50 tablets (5 X 10) unit dose pack, Manufactured for: AvKARE, Inc., Pulaski, TN 38478, UPC 5026868815, NDC 50268-688-15
Compare with the code on your package — it is the most precise check available.
Drug: Quinapril
Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.
CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.
CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.
CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.
CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.
Out of specification for dissolution.
Failed Content Uniformity Specifications
Presence of a foreign substance.
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.